Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

  • STATUS
    Recruiting
  • End date
    Jul 27, 2032
  • participants needed
    666
  • sponsor
    UNICANCER
Updated on 7 August 2021
cancer
estrogen
carcinoma
growth factor
oophorectomy
progesterone
epidermal growth factor receptor
HER2
EGFR
carcinoma in situ
lobular carcinoma
human epidermal growth factor
treated by
tamoxifen
progesterone receptor
erbb2
epidermal growth factor
estrogen receptor
cish
breast carcinoma
ductal carcinoma in situ
lobular carcinoma in situ
breast-conserving surgery
mammogram
ductal carcinoma
ki-67
chromogenic in situ hybridization
breast irradiation
re-excision

Summary

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to 13 % with radiotherapy. Half of the recurrences occurred as invasive disease. Whereas in the comparative trials, WBRT did not impact on overall survival, survival of patients who recurred with invasive cancers was impaired in comparison to patients who did not recur, or to patients with DCIS-only recurrences.

Using criteria based on age, tumor size, nuclear grade, and margins status, several trials and cohort studies failed to identify subgroups of patients at low risk, who could be safely spared the need for WBRT. The Radiation Therapy Oncology Group (RTOG) DCIS trial included patients treated with BCS for low- or intermediate grade DCIS revealed by unifocal microcalcifications, size 25 mm, margins 3 mm, and no residual microcalcifications after surgery. The 5-year rates of IBR were 3.5 % without radiotherapy, versus 0.4 % with radiotherapy, and 6.7 % and 0.9 % at 7 years, respectively (p <0.001). Sixty percent of the patients received tamoxifen in both groups.

Several studies showed that the same molecular classes were identified in DCIS as in invasive cancers. Studies suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested in the Eastern Cooperative Oncology Group (ECOG) trial, showing a 10% IBR rate at ten years in patients with a low-risk.

Identifying very low-risk DCIS, using biological markers in addition to the clinical and histological markers of low-risk DCIS, could help to select patients who could be safely avoided WBRT following BCS. It would avoid over-treatment in these women and could decrease the cost of management.

Details
Condition Ductal Carcinoma In Situ, Mastectomy, Adenocarcinoma, Breast Cancer, Partial Mastectomy, Breast Cancer Diagnosis, Ductal Carcinoma In Situ (DCIS), Malignant Adenoma, Low Risk DCIS, Radiotherapy Omission, breast carcinoma, cancer, breast, breast conserving surgery, breast-conserving surgery, dcis
Treatment Radiotherapy, No Radiotherapy
Clinical Study IdentifierNCT03878342
SponsorUNICANCER
Last Modified on7 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Woman aged 50 years
ECOG performance status 2
Microcalcifications on pre-biopsy mammography, unifocal, 25 mm or opacity without microcalcifications and no clinical palpable tumour
Absence of suspicious residual microcalcifications either on post-biopsy/ preoperative localization mammography, or on post-operative mammography Note: if absence of residual microcalcifications on post-biopsy/pre-operative mammography, post-operative mammography is not mandatory
Breast-conserving surgical excision
Histologically proven DCIS of the breast without an invasive component; Note Incidental histological finding of DCIS lesions developed within a benign breast lesion as well as an association with classical lobular carcinoma in situ (LCIS) associated with the DCIS are accepted
Free margins (2 mm), or free margins following re-excision
Low or Intermediate nuclear grade; Note: In case of nuclear grade heterogeneity within the same sample or between the biopsy or the surgical specimen, the highest nuclear grade score will prevail
Tumour tissue sample availability; Note: Surgical specimen is mandatory unless no residual disease on the surgical specimen. In this instance, the initial diagnosis biopsy is required
Absence of extensive necrosis (30% of the lumen diameter)
Immunohistochemical characteristics of luminal A subtype: ER10 %, PR 20 %, HER2 negative (0/1+) or 2+ not amplified (confirmed by fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)), Ki67 <15%
Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations and including follow-up
Written informed consent
Affiliation to the French social security

Exclusion Criteria

Previous invasive breast cancer including contralateral breast cancer, either metachronous or synchronous
Endocrine treatment for breast cancer
Previous DCIS except contralateral DCIS in complete and continuous remission for more than 5 years
Previous other cancers (except basal-cell, carcinoma in situ of the cervix or endometrium), not in complete and continuous remission for more than 10 years
Known breast-cancer predisposing germ-cell mutation
Palpable tumour with a diagnosis of DCIS on biopsy
Bloody nipple discharge
Histological size >25 mm in one or multiple foci
High nuclear grade, including high nuclear grade in heterogeneous tumours;either on biopsy or on surgical specimen
Presence of tumour cells in lymph nodes detected using H&E or immunohistochemical examination (if lymph node sentinel biopsy or dissection has been performed)
Associated microinvasive or invasive component
Absolute contra-indication to whole-breast irradiation as determined by the referring physician
Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study
Pregnant women or breast feeding mothers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note